← Back to news
Y

Yahoo Finance

Is The Walt Disney Company (DIS) One of the Best Inexpensive Stocks to Invest in Right Now?

Y

Is Micron Technology (MU) One of the Best Inexpensive Stocks to Invest in Right Now?

Y

Dollar General Beats Earnings Estimates. The Stock Is Falling Anyway.

Y

Chief Risk Officer Sells 11,250 Shares of Regional Insurer, According to Latest SEC Filing

Y

Abivax stock plunges on cancer signal in ulcerative colitis trial

Y

Is Pfizer Inc. (PFE) Expanding Its Cancer Pipeline Through a Landmark Innovent Partnership?

Y

Gilead Sciences, Inc. (GILD) Gains Attention as Livdelzi Demonstrates Long-Term Efficacy and Safety

Y

GSK plc (GSK) Launches Ask2BSure Meningitis Awareness Campaign With Celebrity Advocates

Y

Why Zoetis Inc. (ZTS) Was Downgraded Following Steep Market Selloff?

Y

Why Canaccord Reduced Prestige Consumer Healthcare Inc. (PBH) Price Target After Q4 Weakness

Y

Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty

Y

Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo

Y

Dell Stock Is the New Nvidia of AI Infrastructure

Y

Franklin Templeton Taps MoonPay to Bring Stablecoin Cash Into Tokenized Funds

Y

The SpaceX IPO Is Whipping Space Stocks Into a Frenzy

Y

How Victoria’s Secret Engineered the Turnaround That Sent Stock Soaring

Y

Stocks Pressured by Uncertainty of US-Iran Ceasefire Prospects

Y

Signet Jewelers Q1 Earnings Call Highlights

Y

Dollar General Q1 net income rises 13.3%, lifts FY26 EPS outlook

Y

Bitcoin Price Could Hit $2M, Says Tom Lee — Here's How

Y

Solvay and Viridis sign LoI for rare earth supply

Y

Hewlett Packard Enterprise Rockets 25%, Super Micro Computer Climbs 5% as AI Server Demand Lights Up Q2 Earnings

Y

Wedbush lifts IBM price target as AI transformation fears give way to execution confidence

Y

The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains

Y

Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence?

Y

Absa gets approval to buy Standard Chartered Uganda assets

Y

The record-setting S&P 500 is putting up some impressive stats: By the numbers

Y

Salesforce (CRM) Shows Narrative Divergence Amid Anthropic’s Developments

Y

Tech Tuesday: Coppel Teams with First Insight

Y

Netflix Nearing 52-Week Low: Buy, Sell or Hold?

Y

KB (KB) Q1 2026 Earnings Call Transcript

Y

Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess?

Y

Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

Y

Evaluating Zoom’s (ZM) Event-Driven Trade

Y

Is Fold Holdings, Inc. (FLD) Under Pressure After Revenue Drops 21% in Q1 2026?

Y

Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data?

Y

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

Y

Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results

Y

Is Expensify, Inc. (EXFY) Strengthening Its Expense Ecosystem Through New VAT Reclaim Partnership?

Y

Covenant (CVLG) Q1 2026 Earnings Transcript

Y

GoPro, Inc. (GPRO) Stock Focus Shifts to Diversification Beyond Action Cameras

Y

Target vs Walmart: Both Fighting For The Same Customer, Only One Wins

Y

Business Owners: The One Tax Move Financial Advisors Say You Can’t Skip Before Year-End

Y

Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity

Y

Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?

Y

Is ESS Tech, Inc. (GWH) Still a Buy After Softer Q1 Results and Lower Price Target?

Y

Is Takeda Pharmaceutical Company Limited (TAK) Facing Major Legal Risk After U.S. Jury Rules on Generic Drug Delay?

Y

Is Twist Bioscience Corporation (TWST) a Strong Buy After Guggenheim Lifts Price Target?

Y

Is Kymera Therapeutics, Inc. (KYMR) a Long-Term Biotech Winner After New Buy Rating and Coverage Launch At Canaccord?

Y

MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA Progress

Y